Samarth Kulkarni - Aug 16, 2022 Form 4 Insider Report for CRISPR Therapeutics AG (CRSP)

Role
Chief Executive Officer, Director
Signature
/s/ Elizabeth Ryland Waldinger, attorney-in-fact
Stock symbol
CRSP
Transactions as of
Aug 16, 2022
Transactions value $
$0
Form type
4
Date filed
8/18/2022, 05:37 PM
Previous filing
Jul 29, 2022
Next filing
Aug 31, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CRSP Restricted Stock Units Award $0 +25K $0.00 25K Aug 16, 2022 Common Shares 25K Direct F1, F2
transaction CRSP Performance-based Restricted Stock Units Award $0 +150K $0.00 150K Aug 16, 2022 Common Shares 150K Direct F3, F4, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.
F2 The restricted stock units shall vest in full on August 16, 2025, subject to continued service to the Company or any of its subsidiaries.
F3 Each performance-based restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.
F4 Represents the maximum number of shares of CRSP Common Shares that may be awarded upon the achievement of performance conditions.
F5 This grant is subject to both time- and performance-based vesting. Performance-based restricted stock units will vest subject to the terms and conditions of the grant agreement evidencing the award and the Company's 2018 Stock Option and Incentive Plan. The performance conditions shall be deemed satisfied subject to achievement of certain share price targets on or before the third anniversary of the date of grant. All of the performance-based restricted stock units that have satisfied the applicable performance-based criteria shall be deemed vested on the third anniversary of the date of grant, subject to continued service to the Company or any of its subsidiaries through such date.